Chemical formula: C₂₃H₂₄N₄O₃ Molecular mass: 404.47 g/mol PubChem compound: 52938427
Ozanimod interacts in the following cases:
The coadministration of gemfibrozil (a strong inhibitor of CYP2C8) 600 mg twice daily at steady state and a single dose of ozanimod 0.46 mg increased exposure (AUC) of the major active metabolites by approximately 47% to 69%. Caution should be exercised for concomitant use of ozanimod with strong CYP2C8 inhibitors (e.g. gemfibrozil, clopidogrel).
The coadministration of rifampin (a strong inducer of CYP3A and P-gp, and a moderate inducer of CYP2C8) 600 mg once daily at steady state and a single dose of ozanimod 0.92 mg reduced exposure (AUC) of major active metabolites by approximately 60% via CYP2C8 induction which may result in reduced clinical response. The coadministration of CYP2C8 inducers (i.e., rifampin) with ozanimod is not recommended.
The potential for clinical interaction with MAO inhibitors has not been studied. However, the coadministration with MAO-B inhibitors may decrease exposure of the major active metabolites and may result in reduced clinical response. The coadministration of MAO inhibitors (e.g., selegiline, phenelzine) with ozanimod is not recommended.
An inhibitor of the BCRP (ciclosporin) doubled the exposure (AUC) of the minor active metabolites which may subsequently lead to a similar increase in the major active metabolites and increase the risk of adverse reactions. The coadministration of BCRP inhibitors (e.g. ciclosporin and eltrombopag) with ozanimod is not recommended.
In healthy subjects, a single dose of ozanimod 0.23 mg with steady state propranolol long acting 80 mg once daily or diltiazem 240 mg once daily did not result in any additional clinically meaningful changes in HR and PR interval compared to either propranolol or diltiazem alone. Caution should be applied when ozanimod is initiated in patients receiving treatment with a beta-blocker or a calciumchannel blocker. Patients on other bradycardic medicinal products and on antiarrhythmic medicinal products (which have been associated with cases of torsades de pointes in patients with bradycardia) have not been studied with ozanimod.
During and for up to 3 months after treatment with ozanimod, vaccination may be less effective. The use of live attenuated vaccines may carry a risk of infections and should, therefore, be avoided during and for up to 3 months after treatment with ozanimod.
No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. The use of live attenuated vaccines should be avoided during and for 3 months after treatment with ozanimod.
If live attenuated vaccine immunizations are required, these should be administered at least 1 month prior to initiation of ozanimod. Varicella Zoster Virus (VZV) vaccination of patients without documented immunity to VZV is recommended prior to initiating treatment with ozanimod.
Anti-neoplastic, immunomodulatory or non-corticosteroid immunosuppressive therapies should not be coadministered due to the risk of additive immune system effects.
In MS clinical studies, patients who received ozanimod were not to receive concomitant antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS. Concomitant use of ozanimod with any of these therapies would be expected to increase the risk of immunosuppression. When switching to ozanimod from immunosuppressive medicinal products, the half-life and mode of action must be considered to avoid an additive immune effect whilst at the same time minimizing the risk of disease reactivation. Ozanimod can generally be started immediately after discontinuation of interferon (IFN).
In MS clinical studies, hypertension was more frequently reported in patients treated with ozanimod than in patients treated with IFN β-1a IM and in patients receiving concomitant ozanimod and SSRIs or SNRIs. Blood pressure should be regularly monitored during treatment with ozanimod.
Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain caused by the John Cunningham virus (JCV) that typically occurs in patients who are immunocompromised and may lead to death or severe disability. JCV infection resulting in PML has been observed in patients treated with MS therapies and has been associated with some risk factors (e.g., polytherapy with immunosuppressants, severely immunocompromised patients). Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
Physicians should be vigilant for clinical symptoms or MRI findings that may be suggestive of PML. MRI findings may be apparent before clinical signs or symptoms. If PML is suspected, treatment with ozanimod should be suspended until PML has been excluded. If confirmed, treatment with ozanimod should be discontinued.
Half of the neoplasms reported with ozanimod in the controlled Phase 3 studies consisted of non-melanoma skin malignancies, with basal cell carcinoma presenting as the most common skin neoplasm and reported with similar incidence rates in the combined ozanimod (0.2%, 3 patients) and IFN β-1a (0.1%, 1 patient) groups.
Since there is a potential risk of malignant skin growths, patients treated with ozanimod should be cautioned against exposure to sunlight without protection. These patients should not receive concomitant phototherapy with UV-B-radiation or PUVA-photochemotherapy.
Macular oedema with or without visual symptoms was observed with ozanimod in patients with pre-existing risk factors or comorbid conditions.
Patients with a history of uveitis or diabetes mellitus or underlying/co-existing retinal disease are at increased risk of macular oedema. It is recommended that patients with diabetes mellitus, uveitis or a history of retinal disease undergo an ophthalmological evaluation prior to treatment initiation with ozanimod and have follow up evaluations while receiving therapy. Patients who present with visual symptoms of macular oedema should be evaluated and, if confirmed, treatment with ozanimod should be discontinued. A decision on whether ozanimod should be reinitiated after resolution needs to take into account the potential benefits and risks for the individual patient.
Elevations of aminotransferases may occur in patients receiving ozanimod. Recent (i.e. within last 6 months) transaminase and bilirubin levels should be available before initiation of treatment with ozanimod. In the absence of clinical symptoms, liver transaminases and bilirubin levels should be monitored at Months 1, 3, 6, 9 and 12 on therapy and periodically thereafter. If liver transaminases rise above 5 times the ULN, more frequent monitoring should be instituted. If liver transaminases above 5 times the ULN are confirmed, treatment with ozanimod should be interrupted and only re-commenced once liver transaminase values have normalised.
Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine, should have hepatic enzymes checked and ozanimod should be discontinued if significant liver injury is confirmed. Resumption of therapy will be dependent on whether another cause of liver injury is determined and on the benefits to patient of resuming therapy versus the risks of recurrence of liver dysfunction. Patients with pre-existing liver disease may be at increased risk of developing elevated hepatic enzymes when taking ozanimod.
Ozanimod has not been studied in patients with severe pre-existing hepatic injury (Child-Pugh class C) and must not be used in these patients.
Posterior reversible encephalopathy syndrome (PRES) is a syndrome characterised by sudden onset of severe headache, confusion, seizures and visual loss. Symptoms of PRES are usually reversible but may evolve into ischaemic stroke or cerebral haemorrhage. In controlled clinical trials with ozanimod, one case of PRES was reported in a patient with Guillain-Barré syndrome. If PRES is suspected, treatment with ozanimod should be discontinued.
Ozanimod should be used with caution in patients with severe respiratory disease, pulmonary fibrosis and chronic obstructive pulmonary disease.
There are no or limited amount of data from the use of ozanimod in pregnant women. Studies in animals have shown reproductive toxicity including foetal loss and anomalies, notably malformations of blood vessels, generalised oedema (anasarca), and malpositioned testes and vertebrae (see section 5.3). The receptor affected by ozanimod (sphingosine 1-phosphate receptor) is known to be involved in vascular formation during embryogenesis (see section 5.3).
Consequently, Zeposia is contraindicated during pregnancy (see section 4.3). Zeposia should be stopped 3 months before planning a pregnancy (see section 4.4). If a woman becomes pregnant during treatment, Zeposia must be discontinued. Medical advice should be given regarding the risk of harmful effects to the foetus associated with treatment and ultrasonography examinations should be performed.
Ozanimod/metabolites are excreted in milk of treated animals during lactation (see section 5.3). Due to the potential for serious adverse reactions to ozanimod/metabolites in nursing infants, women receiving ozanimod should not breastfeed.
Zeposia is contraindicated in women of childbearing potential not using effective contraception (see section 4.3). Therefore, before initiation of treatment in women of childbearing potential, a negative pregnancy test result must be available and counselling should be provided regarding the risk to the foetus. Women of childbearing potential must use effective contraception during ozanimod treatment and for 3 months after treatment discontinuation (see section 4.4).
Specific measures are also included in the Healthcare Professional checklist. These measures must be implemented before ozanimod is prescribed to female patients and during treatment.
When stopping ozanimod therapy for planning a pregnancy the possible return of disease activity should be considered (see section 4.4).
No fertility data are available in humans. In animal studies, no adverse effects on fertility were observed (see section 5.3).
Zeposia has no or negligible influence on the ability to drive and use machines.
The most commonly reported adverse reactions are nasopharyngitis (11%), alanine aminotransferase increased (5%), and gamma-glutamyl transferase increased (5%). The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%).
The adverse reactions observed in patients treated with ozanimod are listed below by system organ class (SOC) and frequency for all adverse reactions. Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000).
Table 2. Summary of adverse reactions reported in MS:
Very common: Nasopharyngitis
Common: Pharyngitis, Respiratory tract infection viral, Urinary tract infection*
Uncommon: Herpes zoster
Very common: Lymphopenia
Uncommon: Hypersensitivity (including rash and urticaria*)
Uncommon: Macular oedema**
Common: Bradycardia*
Common: Hypertension*†, Orthostatic hypotension
Common: Alanine aminotransferase increased, Gamma-glutamyl transferase increased, Blood bilirubin increased, Pulmonary function test abnormal***
* At least one of these adverse reactions was reported as serious
† Includes hypertension, essential hypertension, and blood pressure increased (see section 4.4).
** for patients with pre-existing factors (see section 4.4)
*** including pulmonary function test decreased, spirometry abnormal, forced vital capacity decreased, carbon monoxide diffusing capacity decreased, forced expiratory volume decreased
In MS clinical studies, elevations of ALT to 5-fold the upper limit of normal (ULN) or greater occurred in 1.6% of patients treated with ozanimod 0.92 mg and 1.3% of patients on IFN β-1a IM. Elevations of 3-fold the ULN or greater occurred in 5.5% of patients on ozanimod and 3.1% of patients on IFN β-1a IM. The median time to elevation 3-fold the ULN was 6 months. The majority (79%) continued treatment with ozanimod with values returning to <3-fold the ULN within approximately 2-4 weeks. In MS clinical studies, ozanimod was discontinued for a confirmed elevation greater than 5-fold the ULN. Overall, the discontinuation rate due to elevations in hepatic enzymes was 1.1% of patients on ozanimod 0.92 mg and 0.8% of patients on IFN beta-1a IM.
In MS clinical studies, after the initial dose of ozanimod 0.23 mg, the greatest mean reduction from baseline in sitting/supine HR of 1.2 bpm occurred at Hour 5 on day 1, returning to near baseline at Hour 6. With continued dose escalation, there were no clinically relevant HR decreases. In MS clinical studies, bradycardia was reported in 0.5% of patients treated with ozanimod versus 0% of patients treated with IFN β-1a IM on the day of treatment initiation (Day 1). After Day 1, the incidence of bradycardia was 0.8% on ozanimod versus 0.7% on IFN β-1a IM. (see section 5.1). Patients who experienced bradycardia were generally asymptomatic. Heart rates below 40 beats per minute were not observed.
In MS clinical studies, first-degree atrioventricular block was reported in 0.6% (5/882) of patients treated with ozanimod versus 0.2% (2/885) treated with IFN β-1a IM. Of the cases reported with ozanimod, 0.2% were reported on Day 1 and 0.3% were reported after Day 1.
In MS clinical studies, patients treated with ozanimod had an average increase of approximately 1-2 mm Hg in systolic pressure over IFN β-1a IM, and approximately 1 mm Hg in diastolic pressure over IFN β-1a IM. The increase in systolic pressure was first detected after approximately 3 months of treatment initiation and remained stable throughout treatment. Hypertension-related events (hypertension, essential hypertension, and blood pressure increased) were reported as an adverse reaction in 4.5% of patients treated with ozanimod 0.92 mg and in 2.3% of patients treated with IFN β-1a IM.
In MS clinical studies, 3.3% of patients experienced lymphocyte counts less than 0.2 × 109 /L with values generally resolving to greater than 0.2 × 109 /L while remaining on treatment with ozanimod.
In MS clinical studies, the overall rate of infections (35%) with ozanimod 0.92 mg was similar to IFN β-1a IM. Ozanimod increased the risk of upper respiratory tract infections and urinary tract infection. The overall rate of serious infections was similar between ozanimod (1%) and IFN β-1a IM (0.8%) in MS clinical studies.
In MS clinical studies, herpes zoster was reported as an adverse reaction in 0.6% of patients treated with Zeposia 0.92 mg and in 0.2% of patients on IFN β-1a IM.
Minor dose-dependent reductions in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were observed with ozanimod treatment. At months 3 and 12 of treatment in MS clinical studies, median changes from baseline in FEV1 (FVC) in the ozanimod 1 mg group were -0.07 L and -0.1 L (-0.05 L and –0.065 L), respectively, with smaller changes from baseline in the IFN ß-1a group (FEV1: -0.01 L and -0.04 L, FVC: 0.00 L and -0.02 L).
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
